DDW News

Speaker Spotlight: Mary E. McCarthy Rinella, MD

Mary E. McCarthy Rinella, MD

Mary E. McCarthy‑Rinella, MD
Mary E. McCarthy‑Rinella, MD

Professor of Medicine, Feinberg School of Medicine, Northwestern University; Director, Northwestern Fatty Liver Program

Session:

NASH Clinical Trials: What Have We Learned?

DDW Track:

Liver Diseases and Transplantation

Date and Time:

Saturday, May 22, 3:30–5 p.m.

CME:

1.5 hours

Session Description

Tremendous activity in the arena of therapeutic agents for the treatment of NASH has led to an increasing number of trials in advanced development. While there have been some successes, the magnitude of efficacy has been modest. In this state-of-the-art lecture, lessons learned from NASH clinical trials to date will be discussed, including the reasons for failure of late phase trials, which participants will be able to use to better understand the evolution of the NASH landscape. Various barriers to cure in the context of NASH will also be discussed.

This session is included in the cost of registration for DDW 2021 and will be available to watch live or on demand until Aug. 23, 2021. Discounted registration rates are available through March 31. View the DDW Online Planner for the full DDW agenda over May 21-23.

Dr. Rinella’s current focus is in clinical research in the area of non-alcoholic fatty liver disease and NASH both before and after liver transplantation. Her primary clinical focus within the NASH realm is on the associations between NASH and other metabolic comorbidities, emerging NASH therapeutics and the recurrence of NASH after liver transplantation. She recently established NailNASH Consortium, a multicenter consortium to study the risk factors for liver disease recurrence and outcomes of patients transplanted for NASH cirrhosis. You can connect with Dr. Rinalla via live chat during the session.

Leave a Reply

Your email address will not be published.